Filing Flows › Aytu Biopharma (AYTU) › How it makes money
How Aytu Biopharma (AYTU) makes money
Aytu Biopharma (AYTU) made $16.1M of revenue in the fourth quarter fiscal 2026 (Q4 FY26), +6% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q4 FY26 | % of revenue |
|---|---|---|
| Revenue | $16.1M | 100.0% |
| Income tax | $11K | 0.1% |
| Operating cash flow | $4.4M | 27.4% |
| Free cash flow | $4.4M | 27.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q4 FY26 | $16.1M | +6% |
| Q3 FY26 | $12.4M | -33% |
| Q2 FY26 | $15.2M | -6% |
| Q1 FY26 | $13.9M | -16% |
| Q4 FY25 | $15.1M | +4% |
| Q3 FY25 | $18.5M | +32% |
| Q2 FY25 | $16.2M | -14% |
From Aytu Biopharma's 10-K filed Sep 22, 2026 (on EDGAR).
Questions
How does Aytu Biopharma make money?
Aytu Biopharma (AYTU) made $16.1M of revenue in the fourth quarter fiscal 2026 (Q4 FY26), +6% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.